BIOFILCHEM
Biofil Chemicals & Pharmaceuticals financials
- Market cap
- ₹60 Cr
- Sector
- Healthcare
What Biofil Chemicals & Pharmaceuticals Limited does
Biofil Chemicals & Pharmaceuticals manufactures pharmaceutical bulk drugs, APIs and excipients at its Pithampur (Indore) unit, with commercial production running since September 1993. Its product range spans Dried Ferrous Sulphate (crystal, exsiccated and granular forms), Microcrystalline Cellulose Powder (MCCP) and Cellulose Powder, alongside bulk drugs such as Diclofenac Sodium, Aceclofenac, Mefenamic Acid and Fenbendazole. The unit produces, purchases, sells, exports, imports and trades these pharmaceutical and chemical products, with finished goods also supplied as raw material to related entity Cyano Pharma Private Limited.
Segments
- Bulk drugs / APIs
- Pharmaceutical excipients & specialty chemicals
- Manufacturing units
- 1 (Pithampur, Indore) — operations consolidating after disposal of the Sanwer Road, Indore unit
- Commercial production commenced
- September 1993
- Product portfolio
- 9 bulk-drug/API and excipient products across ferrous sulphate, cellulose derivatives and analgesic APIs
- Operations
- Production, export, import and trading of pharmaceutical & chemical products
Quarterly results
Q1 FY27: revenue up 92.1%, net profit down 95.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 14 | 8 | 6 | 14 +462% | 1 −94% | 8 −9% | 12 +92% |
| EBITDA | 0 | 0 | 0 | 0 | 0 +0% | 0 −71% | 0 +291% | 0 +1300% |
| Net profit | 0 | 0 | 0 | 2 | 0 +300% | 0 −50% | 0 +5% | 0 −95% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −21.7% 1Y
1Y: ₹44.07 on 10 Sept 2025 → ₹34.51. High ₹46.34 (3 Feb 2026), low ₹25.79 (30 Mar 2026).
Financials, as filed
Revenue fell 15.8% a year over 2 years, FY24 to FY26. Operating margin held at 2.3%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹40 Cr | ₹33 Cr | ₹28 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Operating margin | 2.0% | 2.5% | 2.3% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹1 Cr | ₹1 Cr | ₹3 Cr |
| Net margin | 1.7% | 1.6% | 9.8% |
| Cash from operations | ₹2 Cr | ₹-2 Cr | ₹-1 Cr |
| Free cash flow | ₹2 Cr | ₹-2 Cr | ₹1 Cr |
| ROCE | 4.9% | 4.1% | 3.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Reserves | ₹-0 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹5 Cr | ₹5 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr |
| Other liabilities | ₹17 Cr | ₹1 Cr | ₹14 Cr | ₹28 Cr | ₹34 Cr | ₹18 Cr |
| Total liabilities | ₹33 Cr | ₹19 Cr | ₹31 Cr | ₹47 Cr | ₹55 Cr | ₹43 Cr |
| Fixed assets | ₹10 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹7 Cr | ₹7 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹23 Cr | ₹9 Cr | ₹22 Cr | ₹38 Cr | ₹48 Cr | ₹36 Cr |
| Total assets | ₹33 Cr | ₹19 Cr | ₹31 Cr | ₹47 Cr | ₹55 Cr | ₹43 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 3% to 24,999.
- Promoters
- 46.8%
- DIIs
- 0.1%
- Public
- 53.1%
Since Jun 2025
- Promoters −0.03 pp
- Public +0.03 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Dec '23: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Mar '24: Promoters 46.8%, FIIs 0.0%, DIIs 0.1%, Public 53.1%.Jun '24: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Sep '24: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Dec '24: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Mar '25: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Jun '25: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Sep '25: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Dec '25: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Mar '26: Promoters 46.8%, DIIs 0.1%, Public 53.1%.Jun '26: Promoters 46.8%, DIIs 0.1%, Public 53.1%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Biofil Chemicals & Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Scope Finance Company Private Limited | 13.90% | unchanged |
| Mid (India) Pharmaceuticals Pvt Ltd | 7.22% | unchanged |
| Starline Equifin Private Limited | 7.07% | −0.44 pp |
| Cyano Finance And Sales Pvt. Ltd. | 5.39% | unchanged |
| Meena Shah | 4.06% | unchanged |
| Niyati Shah | 4.05% | unchanged |
| Ketan Shah | 3.03% | unchanged |
| Sandeep Shah | 2.60% | unchanged |
| Romil Shah | 2.35% | unchanged |
| Ksl And Industries Limited | 1.89% | unchanged |
| Kishor Himmatsinh Jhala | 1.22% | unchanged |
| Smitesh Sanalal Shah | 1.15% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Biofil Chemicals & Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.